Scalp cooling system: efficacy varies with chemotherapy regimen

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • The effectiveness of a sensor-controlled scalp cooling system, DigniCap, appears to depend on the type of chemotherapy regimen and the patient's age.

Why this matters

 

 

  • Hair loss is a common and very distressing adverse effect of chemotherapy, and effective preventive interventions are needed.

Study design

 

 

  • Prospective study that involved 55 women who receive neoadjuvant, adjuvant, or palliative chemotherapy for breast or gynecologic cancer; the goal was to evaluate the effectiveness of a sensor-controlled scalp cooling system (DigniCap) to prevent chemotherapy-induced alopecia.
  • Funding: None disclosed.

Key results

 

 

  • Overall level of effectiveness of the treatment (per World Health Organization alopecia grading system) was 56%, including patients who stopped treatment early.
  • The median score for patient satisfaction was 90%, and a satisfaction score of 80% or better was reported by 64%.
  • 72% of the patients would recommend the scalp-cooling treatment to other patients, 20% didn't know, and 8% would not recommend it.
  • Half of the cohort (52%) wore a head covering at some point during their treatment.
  • Multivariable analysis showed statistically significant predictors of minimal hair loss were younger age (P=.019) and treatment regimens with paclitaxel weekly (P=.012) and paclitaxel–carboplatin (P=.023).

Limitations

 

 

  • No control group.